





Medical Devices Enhanced by Microelectronics to Revolutionize the Treatment of Stroke


Franz Bozsak, CEO and co-founder




Stroke can be caused by different clot types and different removal techniques exist





Stentriever



Aspiration






Removing the clot on the first try


- Improves patient outcome
- Lowers the risk of complications
- Lowers in-hospital cost up to 30%
- Lowers overall cost up to 25%

Sensome's technology to identify clot type






- Array of impedance sensors with incorporated proprietary micro-chip
- AI-powered signal processing algorithm



Low and high frequency currents enable characterization of clot composition




Machine learning algorithm sorts impedance patterns to recognize clots



Micro-electronics technology enables and unmatched miniaturization of our sensor technology





CLOTILD[®] SMART STROKE GUIDEWIRE TO DIFFERENTIATE CLOTS

Clotild[®] is currently not approved anywhere in the world.

Clotild[®] smart guidewire
crossing a red-blood-cell-rich clot
vs.
crossing a fibrin-rich clot

Clotild[®] is currently not approved anywhere in the world.

Click above to watch the video!

Sensome's story so far

2014

Sensome founded, team of 4,
200k€ from Concours Mondial
d'Innovation

2016

Change of indication: from
heart attack to ischemic stroke

2018

World's firsts: measurement of
a human clot and
measurement with the World's
smallest impedance meter

2015

First animal trial and first
financing from Business Angels

2017

First financing round with VCs
(led by Kurma Partners)

2019

International & multi-
disciplinary team of 18 people,
total financing >9m€ private
and 2m€ public funding

SENSOME powered

smart medical devices to revolutionize tomorrow's healthcare

